389 related articles for article (PubMed ID: 36591311)
1. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations.
Bonetto V; Pasetto L; Lisi I; Carbonara M; Zangari R; Ferrari E; Punzi V; Luotti S; Bottino N; Biagianti B; Moglia C; Fuda G; Gualtierotti R; Blasi F; Canetta C; Montano N; Tettamanti M; Camera G; Grimoldi M; Negro G; Rifino N; Calvo A; Brambilla P; Biroli F; Bandera A; Nobili A; Stocchetti N; Sessa M; Zanier ER
Front Immunol; 2022; 13():1070379. PubMed ID: 36591311
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients.
Jarius S; Pache F; Körtvelyessy P; Jelčić I; Stettner M; Franciotta D; Keller E; Neumann B; Ringelstein M; Senel M; Regeniter A; Kalantzis R; Willms JF; Berthele A; Busch M; Capobianco M; Eisele A; Reichen I; Dersch R; Rauer S; Sandner K; Ayzenberg I; Gross CC; Hegen H; Khalil M; Kleiter I; Lenhard T; Haas J; Aktas O; Angstwurm K; Kleinschnitz C; Lewerenz J; Tumani H; Paul F; Stangel M; Ruprecht K; Wildemann B;
J Neuroinflammation; 2022 Jan; 19(1):19. PubMed ID: 35057809
[TBL] [Abstract][Full Text] [Related]
3. CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome.
Guasp M; Muñoz-Sánchez G; Martínez-Hernández E; Santana D; Carbayo Á; Naranjo L; Bolós U; Framil M; Saiz A; Balasa M; Ruiz-García R; Sánchez-Valle R;
Front Immunol; 2022; 13():866153. PubMed ID: 35479062
[TBL] [Abstract][Full Text] [Related]
4. Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale.
Frontera J; Mainali S; Fink EL; Robertson CL; Schober M; Ziai W; Menon D; Kochanek PM; Suarez JI; Helbok R; McNett M; Chou SH;
Neurocrit Care; 2020 Aug; 33(1):25-34. PubMed ID: 32445105
[TBL] [Abstract][Full Text] [Related]
5. Neurological Sequelae of COVID-19.
Ahmad SJ; Feigen CM; Vazquez JP; Kobets AJ; Altschul DJ
J Integr Neurosci; 2022 Apr; 21(3):77. PubMed ID: 35633158
[TBL] [Abstract][Full Text] [Related]
6. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches.
Mahboubi Mehrabani M; Karvandi MS; Maafi P; Doroudian M
Rev Med Virol; 2022 Nov; 32(6):e2334. PubMed ID: 35138001
[TBL] [Abstract][Full Text] [Related]
7. The Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Development of Case Report Forms for Global Use.
McNett M; Fink EL; Schober M; Mainali S; Helbok R; Robertson CL; Mejia-Mantilla J; Kurtz P; Righy C; Roa JD; Villamizar-Rosales C; Altamirano V; Frontera JA; Maldonado N; Menon D; Suarez J; Chou SHY
Neurocrit Care; 2020 Dec; 33(3):793-828. PubMed ID: 32948987
[TBL] [Abstract][Full Text] [Related]
8. Interactions of SARS-CoV-2 with the Blood-Brain Barrier.
Erickson MA; Rhea EM; Knopp RC; Banks WA
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800954
[TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients.
Alexopoulos H; Magira E; Bitzogli K; Kafasi N; Vlachoyiannopoulos P; Tzioufas A; Kotanidou A; Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32978291
[TBL] [Abstract][Full Text] [Related]
10. NeuroCOVID-19: a critical review.
Guedes BF
Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):281-289. PubMed ID: 35976326
[TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection: Pathogenesis and clinical manifestations.
Cárdenas G; Fragoso G; Sciutto E
Curr Opin Pharmacol; 2022 Apr; 63():102181. PubMed ID: 35074661
[TBL] [Abstract][Full Text] [Related]
12. Neuro-Axonal Damage and Alteration of Blood-Brain Barrier Integrity in COVID-19 Patients.
Zingaropoli MA; Iannetta M; Piermatteo L; Pasculli P; Latronico T; Mazzuti L; Campogiani L; Duca L; Ferraguti G; De Michele M; Galardo G; Pugliese F; Antonelli G; Andreoni M; Sarmati L; Lichtner M; Turriziani O; Ceccherini-Silberstein F; Liuzzi GM; Mastroianni CM; Ciardi MR
Cells; 2022 Aug; 11(16):. PubMed ID: 36010557
[TBL] [Abstract][Full Text] [Related]
13. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.
Dewanjee S; Vallamkondu J; Kalra RS; Puvvada N; Kandimalla R; Reddy PH
Mol Neurobiol; 2021 Sep; 58(9):4694-4715. PubMed ID: 34169443
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics.
Leng A; Shah M; Ahmad SA; Premraj L; Wildi K; Li Bassi G; Pardo CA; Choi A; Cho SM
Cells; 2023 Mar; 12(5):. PubMed ID: 36899952
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity.
Virhammar J; Nääs A; Fällmar D; Cunningham JL; Klang A; Ashton NJ; Jackmann S; Westman G; Frithiof R; Blennow K; Zetterberg H; Kumlien E; Rostami E
Eur J Neurol; 2021 Oct; 28(10):3324-3331. PubMed ID: 33369818
[TBL] [Abstract][Full Text] [Related]
16. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up.
Kanberg N; Simrén J; Edén A; Andersson LM; Nilsson S; Ashton NJ; Sundvall PD; Nellgård B; Blennow K; Zetterberg H; Gisslén M
EBioMedicine; 2021 Aug; 70():103512. PubMed ID: 34333238
[TBL] [Abstract][Full Text] [Related]
17. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
18. Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes.
Lennol MP; Ashton NJ; Moreno-Pérez O; García-Ayllón MS; Ramos-Rincon JM; Andrés M; León-Ramírez JM; Boix V; Gil J; Blennow K; Merino E; Zetterberg H; Sáez-Valero J
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769057
[TBL] [Abstract][Full Text] [Related]
19. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians.
Maury A; Lyoubi A; Peiffer-Smadja N; de Broucker T; Meppiel E
Rev Neurol (Paris); 2021; 177(1-2):51-64. PubMed ID: 33446327
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19.
Zingaropoli MA; Pasculli P; Barbato C; Petrella C; Fiore M; Dominelli F; Latronico T; Ciccone F; Antonacci M; Liuzzi GM; Talarico G; Bruno G; Galardo G; Pugliese F; Lichtner M; Mastroianni CM; Minni A; Ciardi MR
Cells; 2023 Sep; 12(18):. PubMed ID: 37759493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
